Tom Wickham

Tom Wickham is Chief Scientific Officer at GentiBio, bringing over 25 years of experience advancing cellular, gene, immuno-biologic, and liposomal therapies from discovery through registration-directed clinical trials. He joined GentiBio from Rubius Therapeutics, where as SVP of R&D he pioneered engineered red-cell platforms and built discovery and preclinical organizations leading to multiple programs and two INDs. Previously, he held senior R&D roles at Merrimack Pharmaceuticals, EMD Lexigen (Merck-Serono), and GenVec. Tom holds a B.S. from Carnegie Mellon University, a Ph.D. from Cornell University, and completed postdoctoral training at Scripps Research Institute.